Can Zepbound Lower Blood Pressure?
Yes, Zepbound (tirzepatide) significantly lowers blood pressure, with reductions of approximately 5-7 mmHg systolic and 4 mmHg diastolic blood pressure, though this benefit comes with an increased risk of hypotension-related adverse events, particularly at higher doses.
Evidence for Blood Pressure Reduction
The blood pressure-lowering effect of tirzepatide is well-established across multiple high-quality studies:
Magnitude of effect: In the SURMOUNT-1 trial, tirzepatide produced a net reduction of 6.8 mmHg systolic and 4.2 mmHg diastolic blood pressure versus placebo at 72 weeks 1. A meta-analysis confirmed dose-dependent reductions: -4.20 mmHg (5 mg), -5.34 mmHg (10 mg), and -5.77 mmHg (15 mg) for systolic pressure 2.
Timing of effect: Blood pressure reduction occurs rapidly, with most decline happening within the first 24 weeks, followed by stabilization through the remainder of treatment 1.
Clinical significance: Participants treated with tirzepatide were substantially more likely to achieve normal blood pressure at 72 weeks (58.0% vs 35.2% with placebo) 1. In the SUMMIT trial of patients with heart failure and obesity, tirzepatide reduced systolic blood pressure by 5 mmHg compared to placebo 3.
Mechanism: Weight Loss-Mediated
Approximately 68-71% of the blood pressure reduction is explained by weight loss 1. The mechanism involves:
- Reduced estimated blood volume (decreased by 0.58 liters) 3
- Decreased circulatory volume-pressure overload 3
- Reduced systemic inflammation (C-reactive protein decreased by 37.2%) 3
The blood pressure effect shifts the entire distribution curve to lower levels, working consistently across baseline blood pressure subgroups 1.
Critical Safety Consideration: Hypotension Risk
The blood pressure-lowering benefit carries a dose-dependent risk of hypotension-related adverse events:
- Tirzepatide increases hypotension-related events (RR = 2.45,95% CI [1.35-4.45]) 4
- Risk is highest at higher doses (RR = 2.58 for 15 mg dose) 4
- While low blood pressure adverse events remain infrequent overall, the rate is higher than placebo 1
Clinical Application Algorithm
For patients with hypertension or elevated blood pressure:
- Tirzepatide provides meaningful blood pressure reduction beyond weight loss alone
- Monitor blood pressure closely during the first 24 weeks when most reduction occurs
- Consider dose adjustment if symptomatic hypotension develops
For patients with normal or low-normal blood pressure:
- Exercise caution, particularly with higher doses (10-15 mg)
- Establish baseline blood pressure and monitor for orthostatic symptoms
- Consider starting at 5 mg dose if hypotension risk is a concern
For patients on antihypertensive medications:
- Anticipate need to reduce or discontinue some blood pressure medications
- Monitor closely during titration phase
- Prioritize maintaining medications with cardiovascular benefits (e.g., ACE inhibitors, ARBs for kidney protection)
Guideline Context
Current 2025 BMJ guidelines note that tirzepatide has uncertain cardiovascular and kidney benefits compared to GLP-1 receptor agonists, despite superior weight loss 5. For patients at higher cardiovascular risk, tirzepatide should generally not replace medications with proven cardiovascular benefits. If switching from a GLP-1 agonist to tirzepatide, continuation of an SGLT-2 inhibitor is indicated 5.
Additional Cardiometabolic Benefits
Beyond blood pressure, tirzepatide improves multiple cardiovascular risk markers 6, 3:
- 32-38% of patients achieve the triple endpoint of ≥5% weight loss, ≥5 mmHg systolic BP reduction, and non-HDL cholesterol <130 mg/dL 6
- Reduces total cholesterol by 3.76-5.93% 2
- Decreases LDL cholesterol and triglycerides while increasing HDL cholesterol 2, 7
- Reduces microalbuminuria and improves kidney function markers 3
- Decreases cardiac biomarkers (troponin T reduced by 10.4%, NT-proBNP trended lower) 3